분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-12-22 17:13:05 , Hit : 939
 Editas Expands CRISPR Capabilities through New Technology Licensing


GEN News Highlights
More »
December 19, 2016

Officials at Editas Medicine say they exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics. These global licensing agreements include intellectual property owned by the Broad Institute of MIT and Harvard (Broad Institute), Harvard University, Massachusetts Institute of Technology (MIT), Wageningen University, the University of Iowa, and the University of Tokyo for the new CRISPR, or clustered regularly interspaced short palindromic repeats, genome-editing system known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.

“We are delighted to expand our global CRISPR  genome-editing leadership and to build on the groundbreaking work of these important academic institutions to develop both the new genome-editing system Cpf1 and advanced forms of Cas9,” said Katrine Bosley, president and CEO of Editas Medicine. “With the addition of these significant advancements, we further develop the strongest and most differentiated platform in the fast-moving field of CRISPR, which enables us to design and develop unprecedented genome editing medicines.”

Cpf1 is a CRISPR genome-editing system that has been recently characterized and engineered and may be applied to make medicines for humans, among other applications. According to Bosley, Cpf1 complements the Cas9 genome-editing system because the Cpf1 protein is structurally distinct, has independent intellectual property, and has several potential benefits. Among these are increasing the number of sites in the genome that can be edited, because Cpf1 has distinct protospacer adjacent motifs. The system has simpler manufacture and delivery because the natural system requires only a short, single CRISPR guide RNA and does not include a trans-activating CRISPR RNA (tracrRNA). It also has increased efficiency and accuracy for some forms of gene repair because it makes staggered DNA cuts.

Under the terms of the combined licenses for Cpf1, advanced forms of Cas9, and additional Cas9-based genome-editing technologies from the Broad Institute, Harvard University, MIT, Wageningen University, the University of Iowa, and the University of Tokyo, Editas Medicine will make total upfront cash payments of $6.25 million and issue a promissory note totaling $10 million that can be settled in stock or cash over a predefined period. In the future, Editas Medicine may make additional payments in cash or stock upon reaching goals and targets related to research and development, commercialization, and market capitalization, and will pay royalties on products based on these technologies.

Bosley also noted that these licenses employ the inclusive innovation model, developed by Broad Institute, Harvard University, and MIT, “which enables Editas Medicine to devote sufficient investment to develop CRISPR-based genome-editing technology to treat human diseases, while enabling broad development of medicines against many diseases.” Under this model, Editas Medicine has a right to exclusively use the technology on targets of its choosing for the development of genomic medicines. After an initial period, other companies may apply.

This past Friday, three developers of treatments based on CRISPR/Cas9 and a company that facilitates nonexclusive licensing of the gene-editing technology said today they have signed a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9. The three developers—CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences—and ERS Genomics entered into the agreement with CRISPR IP co-owners, the Regents of the University of California (UC), Emmanuelle Charpentier, Ph.D., of the Helmholtz Centre for Infection Research, and the University of Vienna.







1207   Cancer Onset May Be Caused by Immune System Fighting Viruses  이성욱 2017/08/25 872
1206   Resistance to HIV Engineered Via CRISPR  이성욱 2017/08/07 880
1205   Zika Update  이성욱 2016/03/15 884
1204   [바이오토픽] 드디어 올 것이 왔다: CRISPR, 생존가능 인간배아의 질병초래 유전자 교정 성공  이성욱 2017/08/03 886
1203   “유전자 치료 법률 금지 한국 유일” vs “생명체 설계도 바꾸는 건 문제”  이성욱 2017/08/28 890
1202   CRISPR Corrects RNA-based Disease Defects  이성욱 2017/08/14 894
1201   [바이오토픽] 중국, 최초의 유전체편집 아기 탄생  이성욱 2018/11/27 903
1200   CRISPR Fixes Stem Cells Harboring Blindness-Causing Defect  이성욱 2016/02/01 907
1199   First In Vivo Human Genome Editing to Be Tested in New Clinical Trial  이성욱 2017/05/18 911
1198   [바이오토픽] FDA 자문위원회, CAR-T(chimeric antigen receptor T cell) 승인 만장일치로 권고  이성욱 2017/07/14 919
1197   ‘단세포 인공생명체’ 눈앞에 성큼  이성욱 2017/03/11 921
1196   유전자치료제 '인보사' 연골재생 입증못해도 허가받은 까닭  이성욱 2017/07/14 925
1195   CRISPR Can Tag RNA  이성욱 2016/03/26 930
1194   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 930
1193   Revisiting CAR T-Cells for Treating HIV Shows Promise  이성욱 2016/07/19 932
1192   독감바이러스의 ‘RNA 도둑질’  이성욱 2017/05/08 933
1191   RNA May Surpass DNA in Precision Medicine  이성욱 2016/03/23 937
1190   UPDATE 2-Gilead experimental drug fights all forms of hep C: data  이성욱 2015/09/24 939
  Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 939
1188   노벨 생리의학상 유감(有感)  이성욱 2015/10/06 940

[1][2][3] 4 [5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN